Please assess the completion status of the following clinical trial:

Trial Title: Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. The participant has read the informed consent form, has understood the relevant aspects of the clinical study, and grants his/her authorization to participate by signing the informed consent form prior to the inclusion in the clinical study and the performance of any procedure.~2. Male and female participants above 18 years up to 60 years.~3. Female participants of childbearing potential must be practicing an acceptable method of birth control and must have a negative urine pregnancy test at enrollment with confirmation at the Allocation Visit.~4. Participants are in good health, i.e., the medical record, vital signs, physical examination, and laboratory parameter assessments do not show any abnormal deviations impeding the participation in the clinical study.~5. Participants requiring extraction of 3 or more third molars with 2 mandibular impacted third molars.~6. Clinical and radiological diagnosis of impacted lower third molars.~7. Class I and Class II molars according to Pell and Gregory's classification (Gay Escoda et al. 2004).~8. Participants must be able to swallow the IMPs.~Exclusion Criteria at Enrollment:~1. Findings in the medical record, vital signs, and/or physical examination demonstrating abnormal conditions of participant's general state of health preventing his/her participation in the clinical study according to the investigator's opinion.~2. Participant unable to speak, read, or write in Spanish language.~3. Clinical laboratory parameters exceed the pre-defined alert ranges (i.e., 1 standard deviation above or below the upper/lower limit of the normal ranges).~4. Known hypersensitivity to the IMPs, the anesthetic to be used during surgery, or to the rescue medication (ibuprofen, ketorolac).~5. Known alcohol or drug abuse in the last 6 months or any history of seizures. Alcohol abuse is defined as the consumption of more than 3 ounces (about 90 milliliters) of liquor or spirits or 18 ounces (about 530 milliliters) of beer per day, for 5 consecutive days during the 6-month period. Drug abuse is defined as the use of any recreational drug for 5 consecutive days during the 6 month period.~6. Participants who take analgesic medication for chronic pain, monoamine oxidase inhibitors, tricyclic antidepressants, neuroleptics, or other drugs that reduce the seizure threshold within 4 weeks of enrollment.~7. Pregnant or lactating women.~8. Participants who received systemic corticosteroids or opioid analgesics less than 2 weeks before surgery.~9. Participants with molars linked to the mandibular canal.~10. Participants requiring immediate dental procedures other than third and fourth molars extraction,~    Exclusion Criteria at the Allocation Visit:~11. Participant received a long-acting non-steroidal anti-inflammatory drug within 24 hours or 5 times the elimination half-life of that drug prior to surgery, whatever the longer.~12. Participant received any analgesic medication other than short-acting pre-operative or intra-operative anesthetic agents within 24 hours before taking IMPs.~13. Participant received more than 300 mg of lidocaine in total.~14. Participant received any analgesic medication other than the IMPs immediately after the oral surgical procedure was completed.~15. Baseline pain intensity of the participant after oral surgical procedure remains below 5 points on the 11-point NRS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Tramadol/Diclofenac 50/50 (Type: EXPERIMENTAL): Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
- Tramadol/Diclofenac 25/25 (Type: EXPERIMENTAL): Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
- Tramadol 50 (Type: ACTIVE_COMPARATOR): Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
- Diclofenac 50 (Type: ACTIVE_COMPARATOR): Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction

Based on this trial design, predict the completion outcome and termination type (if applicable).